Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Profit After Tax (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Profit After Tax for 10 consecutive years, with -$42.5 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 29.49% to -$42.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$223.1 million through Dec 2025, up 13.77% year-over-year, with the annual reading at -$223.1 million for FY2025, 13.77% up from the prior year.
  • Profit After Tax hit -$42.5 million in Q4 2025 for Rocket Pharmaceuticals, up from -$50.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$34.5 million in Q2 2021 to a low of -$69.6 million in Q2 2024.
  • Historically, Profit After Tax has averaged -$55.9 million across 5 years, with a median of -$59.0 million in 2023.
  • Biggest five-year swings in Profit After Tax: tumbled 72.35% in 2021 and later grew 29.49% in 2025.
  • Year by year, Profit After Tax stood at -$44.2 million in 2021, then tumbled by 50.8% to -$66.7 million in 2022, then grew by 10.59% to -$59.7 million in 2023, then decreased by 1.12% to -$60.3 million in 2024, then increased by 29.49% to -$42.5 million in 2025.
  • Business Quant data shows Profit After Tax for RCKT at -$42.5 million in Q4 2025, -$50.3 million in Q3 2025, and -$68.9 million in Q2 2025.